Pure Global
NCT00778193

Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on the Healing of Stomach and Intestinal Ulcers

A Randomized, Blinded, Placebo-Controlled Study of the Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on Gastroduodenal Healing
Research Associates of New York, LLP·Phase 4·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Gastroduodenal Ulcer
Drug/Device/Intervention
Naproxen
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Research Associates of New York, LLP
Location
New York, United States of America
Timeline & enrollment
Phase
Phase 4
Start date
Oct 01, 2007
End date
Mar 01, 2008
Enrollment
125 participants
Summary

Gastroduodenal ulcers are extremely common in the community today. Though much has been
 written and observed concerning how ulcers form, not much has been described in the human
 model concerning how these ulcers heal. As numerous patients already suffer from
 gastrointestinal ulcers, further clarification of ulcer healing would be valuable in the
 treatment and management of these patients. The goal of this study is to investigate the
 effects of naproxen, aspirin, celecoxib, and clopidogrel on biopsy-induced gastroduodenal
 lesions in order to elucidate the mechanisms of ulcer healing. This single site,
 single-blind, randomized, placebo-controlled, one-week prospective study will examine ulcer
 healing through endoscopic, immunohistologic, and molecular PCR modalities.

ICD-10 classifications
Gastric ulcerGastrojejunal ulcerGastric ulcer : chronic or unspecified with haemorrhageGastrojejunal ulcer : chronic or unspecified with haemorrhageGastrojejunal ulcer : unspecified as acute or chronic, without haemorrhage or perforation
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT00778193
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT00778193 through Pure Global AI's free database. This Phase 4 trial is sponsored by Research Associates of New York, LLP and is currently Completed. The study focuses on Gastroduodenal Ulcer. Target enrollment is 125 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.